Anaplastic large cell lymphoma historical perspective

Jump to: navigation, search

Anaplastic large cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anaplastic large cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anaplastic large cell lymphoma historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anaplastic large cell lymphoma historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anaplastic large cell lymphoma historical perspective

CDC on Anaplastic large cell lymphoma historical perspective

Anaplastic large cell lymphoma historical perspective in the news

Blogs on Anaplastic large cell lymphoma historical perspective

Directions to Hospitals Treating Anaplastic large cell lymphoma

Risk calculators and risk factors for Anaplastic large cell lymphoma historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2], Kamal Akbar, M.D.[3]

Overview

Anaplastic lymphoma was first described by Stien et al in 1985. In 2008, the World Health Organization (WHO) added anaplastic lymphoma kinase (ALK) negative anaplastic large cell lymphoma and anaplastic lymphoma kinase positive large B-cell lymphoma as transitional bodies in the peripheral T-cell lymphoma classification.[1][2]

Historical Perspective

  • Anaplastic large cell lymphoma was first described by Stein et al in 1985 and described it as neoplastic proliferation of lymphoid cells that appears anaplastic. When tumor cells always showed labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen[3]
  • In 1988, ALCL was added to the revised Kiel classification
  • In 1994, it was included in the Revised European-American Lymphoma (REAL) classification[3]
  • Then in 1997 Delsol discovered anaplastic lymphoma kinase-(ALK-) positive large B-cell lymphoma (ALK+ LBCL)
  • In 2008, the World Health Organization (WHO) added anaplastic lymphoma kinase (ALK) negative anaplastic large cell lymphoma and anaplastic lymphoma kinase positive large B-cell lymphoma as provisional entities in the peripheral T-cell lymphoma classification.[1][2]

References

  1. 1.0 1.1 "Anaplastic large cell lymphoma, ALK-negative".
  2. 2.0 2.1 Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma. Hindawi Publishing Corporation. http://www.hindawi.com/journals/ah/2012/529572/#B1 Accessed on October 13, 2015
  3. 3.0 3.1 Montes-Mojarro IA, Steinhilber J, Bonzheim I, Quintanilla-Martinez L, Fend F (2018). "The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)". Cancers (Basel). 10 (4). doi:10.3390/cancers10040107. PMC 5923362. PMID 29617304.

Linked-in.jpg